ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Regulatory news

EU · EU licence (European Commission)

Eltrombopag (Eltrombopag Accord)

Eltrombopag Accord is indicated for the treatment of adult patients with primary immune thrombocytopenia (ITP) who are refractory to other treatments (e.g. corticosteroids, immunoglobulins).Eltrombopag Accord is indicated for the treatment of paediatric patients aged 1 year and above with primary immune thrombocytopenia (ITP) lasting 6… Show the full indication

Eltrombopag Accord is indicated for the treatment of adult patients with primary immune thrombocytopenia (ITP) who are refractory to other treatments (e.g. corticosteroids, immunoglobulins).Eltrombopag Accord is indicated for the treatment of paediatric patients aged 1 year and above with primary immune thrombocytopenia (ITP) lasting 6 months or longer from diagnosis and who are refractory to other treatments (e.g. corticosteroids, immunoglobulins).Eltrombopag Accord is indicated in adult patients with chronic hepatitis C virus (HCV) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy.

Generic
CHMP opinion 30 Jan 2025 → EU licence 28 Mar 2025 · Accord Healthcare S.L.U.

Research

Oncology · Cancer · 2026-11-01

In 110 patients aged ≥60 with newly diagnosed AML, eltrombopag from day 11 after induction chemotherapy did not improve overall survival vs placebo (HR 1.59; 95% CI 0.65–3.89; p=.31), but median platelet transfusions fell (8 vs 10) without more grade 3/4 adverse events.

RCTn = 110
Pigneux et al. Eltrombopag during induction chemotherapy in older patients with newly diagnosed acute myeloid leukemia is safe and reduces platelet transfusion requirements: The EPAG-2015 French Innovative Leukemia Organization phase 2 randomized trial
Haematology · Am J Hematol · 2026-07-19

Final 2-year analysis of a phase 3 RCT in 197 untreated patients with severe aplastic anaemia: adding eltrombopag to horse ATG plus cyclosporine raised complete response (62.4% vs 35.3%). 2-year overall survival of 91% vs 86% was not significantly different.

RCTn = 197
Risitano et al. Eltrombopag Added to Standard Immunosuppressive Treatment as Front-Line Therapy for Severe Aplastic Anemia: Long-Term Outcomes of the Phase-3 Randomized Superiority EBMT-SAAWP RACE Study

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.